Peer-Reviewed Manuscripts
Please find a list of peer-reviewed manuscripts the PRCSG has completed below.
View our Authorship Policy and PRINTO and PRCSG Publication Policy
| Article | Author(s) | Journal | Year |
|---|---|---|---|
| Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS) | Lam, E., Berezny, K., Bishop, C.J., Lomax, K.G., Liva, S. G., Brunner, H.I., Paller, A.S., Diaz, L. Z., Wine Lee, L., Rubin, C., Carrasco, R., Imundo, L., Majlessi, A., Smith, V., Zhang, R., Leu, J.H., on behalf of the U-POPS Study Group | Rheumatol Ther (2025). https://doi.org/10.1007/s40744-025-00820-3 | 2025 |
| Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial | Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) | Arthritis & Rheumatology | 2025 |
| Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial | Brunner, H.I., Antón, J., Calvo-Penadés, I., Dimelow, R., Horneff, G., Kamphuis, S., Marino, R., van Maurik, A., Minden, K., Mori, M., Ocran-Appiah, J., Wilkinson, C., Yamasaki, Y., Assudani, D. and for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators | Arthritis Care Res. Accepted Author Manuscript. | 2025 |
| Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting | Weiss PF, Ruperto N, Quebe-Fehling E, Shew A, Pricop L, Pieterse CC, Brunner HI; Paediatric Rheumatology INternational Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) Investigative Sites. | J Rheumatol. 2025 Sep 15:jrheum.2025-0294. doi: 10.3899/jrheum.2025-0294. Epub ahead of print. PMID: 40953957. | 2025 |
| Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial | Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud-Mendoza, Alberto Spindler, Yulia Vyzhga, Iris Reyhan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Peter Chiraseveenuprapund, Daniel J Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Kevin D. Roberts, Gosford Sawyerr, Andreas Blum, Andrea Shapiro, Annette Diehl, Abbas Ebrahim, Pascal Klaus, Alberto Martini, Hermine I. Brunner, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) | ACR Open Rheumatology | 2025 |
| Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post-Hoc Analysis from a Phase III Trial | Alessandro Consolaro, Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud-Mendoza, Alberto Spindler, Yulia Vyzhga, Ekaterina Alexeeva, Jeffrey Chaitow, Peter Chiraseveenuprapund, Irina Lazariciu, Lori Stockert, Mary Jane Cadatal, Annette Diehl, and Hermine I Brunner, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) | J Rheumatol. Published online May 1, 2025. doi:10.3899/jrheum.2024-0536 | 2025 |
| Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study | Hermine I Brunner, Jonathan D Akikusa, Eslam Al-Abadi, John F Bohnsack, Alina Lucica Boteanu, Gaelle Chedeville, Ruben Cuttica, Wendy De La Pena, Lawrence Jung, Ozgur Kasapcopur, Katarzyna Kobusinska, Grant S Schulert, Claudia Neiva, Rafael Rivas-Chacon, Juan Cruz Rizo Rodriguez, Monica Vazquez-Del Mercado, Linda Wagner-Weiner, Jennifer E Weiss, Carine Wouters, Holly Posner, Ann Wouters, Cheng Chang, Claire White, Keith Kanik, Shixue Liu, Alberto Martini, Daniel J Lovell, Nicolino Ruperto; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) | Ann Rheum Dis. 2024 Oct 21;83(11):1561-1571. doi: 10.1136/ard-2023-225094 | 2024 |
| Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction | Esraa Eloseily, Alex Pickering, Sanjeev Dhakal, Nicolino Ruperto, Hermine I. Brunner, Alexei A. Grom, Sherry Thornton | Arthritis Care & Research | 2024 |
| Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-term Extension of an Open-label, Phase 3 Study | Hermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, Simone Appenzeller, Vyacheslav Chasnyk, Thomas Griffin, Carmen Navarrete Suarez, Sheila Knupp-Oliveira, Andrew Zeft, Yonatan Butbul Aviel, Deirdre De Ranieri, Beth S. Gottlieb, Deborah M. Levy, C. Egla Rabinovich, Clóvis Artur Silva, Yury Spivakovsky, Yosef Uziel, Sarah Ringold, Xie L. Xu, Jocelyn H. Leu, Edwin Lam, Yuhua Wang, Daniel J. Lovell, Alberto Martini and Nicolino Ruperto on behalf of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology INternational Trials Organisation (PRINTO) | The Journal of Rheumatology Aug 2024, jrheum.2024-0298; DOI: 10.3899/jrheum.2024-0298 | 2024 |
| Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study | Hermine I. Brunner, Jonathan Akikusa, Eslam Al-Abadi, John Bohnsack, Alina Lucica Boteanu, Gaëlle Chédeville, Ruben Cuttica, Wendy De La Pena, Lawrence Jung, Özgür Kasapçopur, Katarzyna Kobusińska, Grant Schulert, Cláudia Neiva, Rafael Rivas-Chacon, Juan Cruz Rizo Rodriguez, Mónica Vázquez0-Del Mercado, Linda Wagner-Weiner, Jennifer E Weiss, Carine Wouters, Holly Posner, Ann Wouters, Cheng Chang, Claire White, Keith S Kanik, Shixue Liu, Alberto Martini, Daniel J Lovell, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) | Ann Rheum Dis. 2024; 0:ard-2023-225094v1-ard-2023-225094 | 2024 |
| S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis | Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Anton, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel J Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert L Wong, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, and Alexei A Grom on behalf of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO) | Arthritis Research & Therapy (2024) 26:125 https://doi.org/10.1186/s13075-024-03347-0 | 2024 |
| Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis | Hermine I. Brunner, Nicolino Ruperto, Athimalaipet V. Ramanan, Gerd Horneff, Kirsten Minden, Inmaculada Calvo Penades, Ekaterina Alexeeva, Gavin Cleary, Sara M. Stern, Isabelle Kone-Paut, María del Rocío Maldonado Velázquez, C. Egla Rabinovich, Agustin Remesal, Clovis Artur Silva, Irina Nikishina, Mauro Zucchetto, Laura Brockwell, Oliver Gordon, Sandra Nagel, Fabrizio De Benedetti, for the PRINTO and PRCSG investigators | Rheumatology (Oxford). 2024 Mar 29:keae180. doi: 10.1093/rheumatology/keae180. Epub ahead of print. PMID: 38552315. | 2024 |
| Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry | Daniel J. Lovell, Nikolay Tzaribachev, Michael Henrickson, Gabriele Simonini, Thomas A. Griffin, Ekaterina Alexeeva, John F. Bohnsack, Andrew Zeft, Gerd Horneff, Richard K. Vehe, Valda Stanevica, Stacey Tarvin, Maria Trachana, Ana Quintero del Rio, Adam M. Huber, Daniel Kietz, Ilonka Orban, Jason Dare, Ivan Foeldvari, Pierre Quartier, Alyssa Dominique, Teresa A. Simon, Alberto Martini, Hermine I. Brunner and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) | Rheumatology (Oxford). 2024 Jan 18:keae025. doi: 10.1093/rheumatology/keae025. Epub ahead of print. PMID: 38243722. | 2024 |
| Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated with Abatacept. | Hermine I Brunner, Nikolay Tzaribachev, Ingrid Louw, Inmaculada Calvo Penades, Francisco Avila-Zapata, Gerd Horneff, Ivan Foeldvari, Daniel J Kingsbury, Maria Eliana Paz Gastanaga, Carine Wouters, Johannes Breedt, Robert Wong, Margarita Askelson, Joe Zhuo, Alberto Martini, Daniel J Lovell, and Nicolino Ruperto for the investigators of the PRINTO and PRCSG networks | Arthritis Car Res (Hoboken). 2023. Epub 2023/05/24. PubMed PMID: 37221146 | 2023 |
| Baricitinib in juvenile idiopathic arthritis: an international multi-centre phase 3, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. | Athimalaipet V Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Sarka Fingerhutova, Jordi Anton, Zhongkai Wang, Gabriella Meszaros, Joana Araujo, Ran Liao, Stuart Keller, Hermine I Brunner, Nicolino Ruperto, on behalf of the JUVE-BASIS investigators and of the Paediatric Rheumatology International Trials Organisation (PRINTO) | Lancet. 2023 Jul 6:S0140-6736(23)00921-2. Epub ahead of print. PMID: 37423231 | 2023 |
| Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials. | Nicolino Ruperto, Daniel J. Lovell, Alberto Berman, Jordi Anton, Diego Oscar Viola, Bernard Lauwerys, Maria Elena Rama, John Bohnsack, Johannes Breedt, Michel Fischbach, Thomas Lutz, Kirsten Minden, Mahmood Ally, Nadina Rubio-Perez, Elisabeth Gervais, Riana Van Zyl, Robert Wong, Margarita Askelson, Alberto Martini, and Hermine I Brunner for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO) | The Journal of Rheumatology July 2023, jrheum.2022-1320. | 2023 |
| Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial | Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, Chasnyk VG, Hufnagel M, Żuber Z, Schulert G, Ozen S, Rakhimyanova A, Ramanan A, Scott C, Sozeri B, Zholobova E, Martin R, Zhu X, Whelan S, Pricop L, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). | Ann Rheum Dis. 2022 Aug 12:annrheumdis-2022-222849. doi: 10.1136/ard-2022-222849. Epub ahead of print. PMID: 35961761. | 2022 |
| Patient-Reported Outcomes Among Patients Aged 2–17 Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: 2-Year Results From an International Phase III Study | Ruperto, N., Lovell, D.J., Berman, A., Ávila-Zapata, F., Horneff, G., Alessio, M., Becker, M.L., Belot, A., Burgos-Vargas, R., Gamir, M.L., Goldenstein-Schainberg, C., Scheibel, I.M., Terreri, M.T., Zemel, L., Zhuo, J., Askelson, M., Wong, R., Martini, A., Brunner, H.I. and (2022), | Arthritis Care Res. Accepted Author Manuscript. https://doi.org/10.1002/acr.24989 | 2022 |
| Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis | Weiss, P.F., Fuhlbrigge, R.C., von Scheven, E., Lovell, D.J., Colbert, R.A., Brunner, H.I. | Arthritis Care Res, 2022. pp 1-7. | 2022 |
| Evolution in the Understanding of Pediatric-Onset Axial Spondyloarthritis | Lovell, D.J. and Brunner, H.I. | Arthritis Care Res, 73: 921-923. | 2021 |
| Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison | Brunner HI, Abud-Mendoza C, Mori M, et al. | RMD Open 2021;7:e001747. doi:10.1136/ rmdopen-2021-001747. | 2021 |
| Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. | Brunner HI, Chen C, Bovis F, De Benedetti F, Espada G, Joos R, Akikusa J, Chaitow J, Boteanu AL, Kimura Y, Rietschel C, Siri D, Smolewska E, Schmeling H, Brown DE, Martini A, Lovell DJ, Huang B, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). | Arthritis Care Res (Hoboken). 2021 Sep;73(9):1264-1274. doi: 10.1002/acr.24384. Epub 2021 Aug 2 | 2021 |
| Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial | Hermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Rubén Cuttica, Vladimir Keltsev, Ricardo M. Xavier, Ruben Burgos-Vargas, et al. | Arthritis & Rheumatology, March 2021. | 2021 |
| Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. | Lovell DJ, Huang B, Chen C, Angeles-Han S, Simon T, Brunner HI. | RMD Open March 2021;7(1):e001435. doi:10.1136/ rmdopen-2020-001435 | 2021 |
| Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. | Lovell DJ, Huang B, Chen C, Angeles-Han S, Simon T, Brunner HI. | RMD Open 2021;7:e001435. doi:10.1136/ rmdopen-2020-001435 | 2021 |
| Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial | Nicolino Ruperto MD, MPH*, Hermine I Brunner MD, MSc, MBA*, Olga Synoverska MD, Tracy V Ting MD, MSc, RhMSUS, Carlos Abud Mendoza MD, Alberto Spindler MD, Yulia Vyzhga MD, Katherine Marzan MD, Lyudmila Grebenkina MD, Irit Tirosh MD, Lisa Imundo MD, Rita Jerath MD, Daniel J Kingsbury MD, Betul Sozeri MD, Sheetal S Vora MD, Sampath Prahalad MD, Elena Zholobova MD, Yonatan Butbul Aviel MD, Vyacheslav Chasnyk MD, Melissa Lerman MD, Kabita Nanda MD, Heinrike Schmeling MD, Heather Tory MD, Yosef Uziel MD, Diego Oscar Viola MD, Holly B Posner MD, Keith S Kanik MD, Ann Wouters MSc, Cheng Chang PhD, Richard Zhang PhD, Irina Lazariciu MSc, Ming-Ann Hsu MPH, Ricardo M Suehiro MD, Alberto Martini MD*, and Daniel J Lovell MD, MPH*, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) | November 09, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)01255-1 | 2021 |
| Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis | Nicolino Ruperto, Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega-Cornejo, Ingrid Louw, Rolando Cimaz, Jason Dare, Graciela Espada, Enrique Faugier, Manuel Ferrandiz, Valeria Gerloni, Pierre Quartier, Clovis Artur Silva, Linda Wagner-Weiner, Yash Gandhi, Julie Passarell, Marleen Nys, Robert Wong, Alberto Martini, and Daniel J. Lovell, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO) | The Journal of Rheumatology Jan 2021, jrheum.200154; DOI: 10.3899/jrheum.200154 | 2021 |
| Open-Label Phase 3 Study of Intravenous Golimumab in Patients With Polyarticular Juvenile Idiopathic Arthritis | Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). | Rheumatology (Oxford). 2021 Oct 2;60(10):4495-4507. doi: 10.1093/rheumatology/keab021. PMID: 33493312; PMCID: PMC8487314. | 2021 |
| Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis | Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, De Benedetti F, for the Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) | Rheumatology (Oxford). 2021 Oct 2;60(10):4568-4580. doi: 10.1093/rheumatology/keab047. PMID: 33506875 | 2021 |
| Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. | Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, in collaboration with the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). | Annals of the Rheumatic Diseases 2020;79:1340–1348. | 2020 |
| Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label 2‐Year Extension of a Phase 3 Trial. | Brunner, H.I., Ruperto, N., Zuber, Z., Cuttica, R., Keltsev, V., Xavier, R.M., Burgos‐Vargas, R., Calvo Penades, I., Silverman, E.D., Espada, G., Ferrandiz Zavaler, M., Kimura, Y., Duarte, C., Job‐Deslandre, C., Joos, R., Douglass, W., Wimalasundera, S., Bharucha, K.N., Wells, C., Lovell, D.J., Martini, A., De Benedetti, F. | Arthritis & Rheumatology. Accepted Author Manuscript. 2020. doi:10.1002/art.41528 | 2020 |
| Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2 – 5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. | Brunner, H.I., Tzaribachev, N, Cornejo, G.V. et al. | Pediatr Rheumatol 18, 19 (2020). | 2020 |
| Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. | Brunner, H.I., Wong, R., Nys, M. et al. | Pediatr Drugs (2020) | 2020 |
| Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis | Brunner, H.I., Wong, R., Nys, M. et al. | Arthritis. Pediatr Drugs (2020). | 2020 |
| Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results. | Hermine I Brunner, Kabita Nanda, Mary Toth, Ivan Foeldvari, John Bohnsack, Diana Milojevic, C Egla Rabinovich, Daniel J Kingsbury, Katherine Marzan, Elizabeth Chalom, Gerd Horneff, Rolf-Michael Kuester, Jason A Dare, Maria Trachana, Lawrence K Jung, Judyann Olson, Kirsten Minden, Pierre Quartier, Mareike Bereswill, Jasmina Kalabic, Hartmut Kupper, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). | Arthritis Care & Research. Vol. 72, No. 10, October 2020 pp 1420-1430. DOI 10.1002/acr.24044 | 2020 |
| Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results. | Hermine I Brunner, Kabita Nanda, Mary Toth, Ivan Foeldvari, John Bohnsack, Diana Milojevic, C Egla Rabinovich, Daniel J Kingsbury, Katherine Marzan, Elizabeth Chalom, Gerd Horneff, Rolf-Michael Kuester, Jason A Dare, Maria Trachana, Lawrence K Jung, Judyann Olson, Kirsten Minden, Pierre Quartier, Mareike Bereswill, Jasmina Kalabic, Hartmut Kupper, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). | Arthritis Care & Research. Vol. 72, No. 10, October 2020 pp 1420-1430 | 2020 |
| Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. | Hermine I. Brunner, Pierre Quartier, Ekaterina Alexeeva, Tamàs Constantin, Isabelle Koné-Paut, 6 7 8 9 10 11 Katherine Marzan, Rayfel Schneider, Nico M. Wulffraat, Vyacheslav Chasnyk, Irit Tirosh, Tilmann Kallinich, 12 13 14 15 16 Jasmin Kuemmerle-Deschner, Carine Wouters, Bernard Lauwerys, Irina Nikishina, Maria Trachana, 17 18 1 19 20 21 Olga Vougiouka, Alberto Martini, Daniel J. Lovell, Jeremy Levy, Eleni Vritzali, and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group | Arthritis & Rheumatology. Vol. 0, No. 0, Month 2020, pp 1–12 DOI 10.1002/art.41436 | 2020 |
| Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study | Hermine I. Brunner, Pierre Quartier, Ekaterina Alexeeva, Tamàs Constantin, Isabelle Koné-Paut, et al. | Arthritis & Rheumatology (December 2020) | 2020 |
| Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. | Lovell DJ, Brunner HI, Reiff AO, Jung L, Jarosova K, Němcová D, Mouy R, Sandborg C, Bohnsack JF, Elewaut D, Gabriel C, Higgins G, Kone-Paut I, Jones OY, Vargová V, Chalom E, Wouters C, Lagunes I, Song Y, Martini A, Ruperto N. | RMD Open. 2020 Jul;6(2):e001208. doi: 10.1136/rmdopen-2020-001208. PMID: 32665432; PMCID: PMC7425194. | 2020 |
| Tocilizumab slows radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: radiographic analysis from two randomized controlled trials. | Malattia C, Ruperto N, Pederzoli S, Palmisani E, Pistorio A, et al. | Arthritis research & therapy 22(1):211. September 2020. | 2020 |
| Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open-label, Randomized Phase IIIb/IV Study. | Quartier P, Alexeeva E, Tamàs C, Chasnyk V, Wulffraat N, Palmblad K, Wouters C, Brunner H, Marzan K, Schneider R, Horneff G, Martini A, Anton J, Wei X, Slade A, Ruperto N, Abrams K; Pediatric Rheumatology International Trials Organization (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG). | Arthritis Rheumatol. 2020 Aug 11. doi: 10.1002/art.41488. Epub ahead of print. PMID: 32783351 | 2020 |
| American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. | Brunner H.I., Holland M.J., Beresford M.W., Ardoin S.P., Appenzeller S., Silva C.A., Flores F., Goilav B., Avar Aydin P.O., Wenderfer S.E., Levy D.M., Ravelli A., Khubchandani R., Avcin T., Klein-Gitelman M.S., Ruperto N., Feldman B.M., Ying J. | Arthritis Care Res 71: 579-590. doi:10.1002/acr.23834 | 2019 |
| Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results. | Brunner, H.I., Nanda, K., Toth, M., Foeldvari, I., Bohnsack, J., Milojevic, D., Rabinovich, C.E., Kingsbury, D.J., Marzan, K., Chalom, E., Horneff, G., Kuester, R.‐M., Dare, J.A., Trachana, M., Jung, L.K., Olson, J., Minden, K., Quartier, P., Bereswill, M., Kalabic, J., Kupper, H., Lovell, D.J., Martini, A., Ruperto, N. | Arthritis Care Res | 2019 |
| Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal. | Leong JY, Chen P, Yeo JG, Ally F, Chua C, Nur Hazirah S, Poh SL, Pan L2, Lai L, Lee ESC, Bathi LDT, Arkachaisri T, Lovell D, Albani S | Pediatric Rheumatology Collaborative Study Group. Ann Rheum Dis. 2019 Sep 20. pii: annrheumdis-2019-216059. | 2019 |
| Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. | Mallalieu, N.L., Wimalasundera, S., Hsu, J.C. et al. | Pediatr Rheumatol (2019) 17: 57. | 2019 |
| Neutropenia During Tocilizumab Treatment Is Not Associated With Infection Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis. | Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Kone-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F. | J Rheumatol. Mar 2019, jrheum. 180795; DOI: 10.3899/jrheum.180795 | 2019 |
| Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. | Ramanan AV, Brunner HI, Ruperto N, Martini A, Cuttica RJ, Weiss JE, Henrickson M, Schmeling H, Anton J, Minden K, Horneff G, Gamir-Gamir ML, Hufnagel M, Douglass W, Wells C, Wimalasundera S, Mallalieu NL, Lovell DJ, De Benedetti F. | Rheumatology, 58: S3, April 2019 | 2019 |
| Clinical trials in children with adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. | Brunner HI, Martini A, Lovell DJ, Ruperto N. | Annals of the Rheumatic Diseases Published Online First: 19 September 2018. doi: 10.1136/annrheumdis-2018-213198 | 2018 |
| Pediatric Rheumatology Collaborative Study Group -- over four decades of pivotal clinical drug research in pediatric rheumatology | H. I. Brunner, L. G. Rider, D. J. Kingsbury, D. Co, R. Schneider, E. Goldmuntz, K. B. Onel, E. H. Giannini, D. J. Lovell, for the PRCSG Advisory Council, S. Peng and S. Yim | Pediatric Rheumatology, 16 45 (1), 2018. | 2018 |
| Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis | H. I. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, A. Berman, I. Calvo Penades, J. Anton, F. Ãvila-Zapata, R. Cuttica, G. Horneff, I. Foeldvari, V. Keltsev, D. J. Kingsbury, D. O. Viola, R. Joos, B. Lauwerys, M. E. Paz Gastanaga, M. E. Rama, C. Wouters, J. Bohnsack, J. Breedt, M. Fischbach, T. Lutz, K. Minden, T. Miraval, M. M. T. M. Ally, N. Rubio-Perez, E. Solau Gervais, R. Zyl, X. Li, M. Nys, R. Wong, S. Banerjee, D. J. Lovell, A. Martini and N. Ruperto | Arthritis Rheumatology, 70 1144-1154 (7), 2018. | 2018 |
| Measuring Disease Damage and Its Severity in Childhood‐Onset Systemic Lupus Erythematosus. | Holland M. J., Beresford M. W., Feldman B. M., Huggins J., Norambuena X., Silva C. A., Susic G., Sztajnbok F., Uziel Y., Appenzeller S., Ardoin S. P., Avcin T., Flores F., Goilav B., Khubchandani R., Klein‐Gitelman M., Levy D., Ravelli A., Wenderfer S. E., Ying J., Ruperto N., Brunner H. I. | Arthritis Care Res, 70: 1621-1629 (11), 2018 | 2018 |
| Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial | K. N. Bharucha, H. I. Brunner, I. Calvo Penades, I. Nikishina, N. Rubio-Prez, S. Oliveira, K. Kobusinska, H. Schmeling, F. Sztajnbok, F. Weller-Heinemann, E. Zholobova, F. Zulian, R. Allen, J. Chaitow, J. Frane, C. Wells, N. Ruperto and F. De Benedetti | The Journal of Rheumatology, (), 2018. | 2018 |
| Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials | N. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, N. M. Wulffraat, G. Horneff, O. Kasapcopur, R. Schneider, J. Anton, J. Barash, R. Berner, F. Corona, R. Cuttica, M. Fouillet-desjonqueres, M. Fischbach, H. E. Foster, D. Foell, S. C. Radominski, A. V. Ramanan, R. Trauzeddel, E. Unsal, J. Levy, E. Vritzali, A. Martini and D. J. Lovell | Annals of the Rheumatic Diseases, 2018;77:1710-1719. | 2018 |
| Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome | F. Minoia, F. Bovis, S. Daví, A. Insalaco, K. Lehmberg, S. Shenoi, S. Weitzman, G. Espada, Y.-J. Gao, J. Anton, T. Kitoh, O. Kasapcopur, H. Sanner, R. Merino, I. Astigarraga, M. Alessio, M. Jeng, V. Chasnyk, K. E. Nichols, Z. Huasong, C. Li, C. Micalizzi, N. Ruperto, A. Martini, R. Q. Cron, A. Ravelli and A. Horne | The Journal of Pediatrics, 189 72 - 78.e3 (Supplement C), 2017. | 2017 |
| Extrapolation or controlled trials in paediatrics: the current dilemma | N. Ruperto, H. I. Brunner, D. J. Lovell and A. Martini | Archives of Disease in Childhood, 102 949-951 (10), 2017. | 2017 |
| Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study | N. Ruperto, H. I. Brunner, Z. Zuber, N. Tzaribachev, D. J. Kingsbury, I. Foeldvari, G. Horneff, E. Smolewska, R. K. Vehe, A. Hazra, R. Wang, C. A. Mebus, C. Alvey, M. Lamba, S. Krishnaswami, T. C. Stock, M. Wang, R. Suehiro, A. Martini and D. J. Lovell | Pediatric Rheumatology, 15 86 (1), 2017. | 2017 |
| Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab | A. A. Grom, N. T. Ilowite, V. Pascual, H. I. Brunner, A. Martini, D. Lovell, N. Ruperto, for the Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group, K. Leon, K. Lheritier and K. Abrams | Arthritis Rheumatology, 68 218-228 (1), 2016. | 2016 |
| Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis | A. Ravelli, F. Minoia, S. Daví, A. Horne, F. Bovis, A. Pistorio, M. Aricó, T. Avcin, E. M. Behrens, F. De Benedetti, L. Filipovich, A. A. Grom, J.-I. Henter, N. T. Ilowite, M. B. Jordan, R. Khubchandani, T. Kitoh, K. Lehmberg, D. J. Lovell, P. Miettunen, K. E. Nichols, S. Ozen, J. Pachlopnick-Schmid, A. V. Ramanan, R. Russo, R. Schneider, G. Sterba, Y. Uziel, C. Wallace, C. Wouters, N. Wulffraat, E. Demirkaya, H. I. Brunner, A. Martini, N. Ruperto, R. Q. Cron, on behalf of the Pediatric Rheumatology International Trials Organization, the Childhood Arthritis Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group and the Histiocyte Society | Arthritis Rheumatology, 68 566-576 (3), 2016. | 2016 |
| Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years | D. J. Lovell, N. Ruperto, R. Mouy, E. Paz, N. Rubio-Pérez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. Saad-Magalhaes, J. Chavez-Corrales, C. Huemer, A. Kivitz, F. J. Blanco, I. Foeldvari, M. Hofer, H.-I. Huppertz, C. Job Deslandre, K. Minden, M. Punaro, A. J. Block, E. H. Giannini, A. Martini, for the Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation | Arthritis Rheumatology, 67 2759-2770 (10), 2015. | 2015 |
| Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial | F. De Benedetti, H. Brunner, N. Ruperto, R. Schneider, R. Xavier, R. Allen, D. E. Brown, J. Chaitow, M. Pardeo, G. Espada, V. Gerloni, B. L. Myones, J. W. Frane, J. Wang, T. H. Lipman, K. N. Bharucha, A. Martini, D. Lovell, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group | Arthritis Rheumatology, 67 840-848 (3), 2015. | 2015 |
| Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial | H. I. Brunner, N. Ruperto, Z. Zuber, C. Keane, O. Harari, A. Kenwright, P. Lu, R. Cuttica, V. Keltsev, R. M. Xavier, I. Calvo, I. Nikishina, N. Rubio-Pérez, E. Alexeeva, V. Chasnyk, G. Horneff, V. Opoka-Winiarska, P. Quartier, C. A. Silva, E. Silverman, A. Spindler, E. Baildam, M. L. Gámir, A. Martin, C. Rietschel, D. Siri, E. Smolewska, D. Lovell, A. Martini, F. De Benedetti, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) | Annals of the Rheumatic Diseases, 74 1110-1117 (6), 2015. | 2015 |
| Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years | D. J. Kingsbury, B. Bader-Meunier, G. Patel, V. Arora, J. Kalabic and H. Kupper | Clinical Rheumatology, 1-9 (), 2014. | 2014 |
| Determinants of Health-Related Quality of Life in Children Newly Diagnosed With Juvenile Idiopathic Arthritis | M. Seid, B. Huang, S. Niehaus, H. I. Brunner and D. J. Lovell | Arthritis Care Research, 66 263-269 (2), 2014. | 2014 |
| Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus | R. Mina, M. S. Klein-Gitelman, S. Nelson, B. A. Eberhard, G. Higgins, N. G. Singer, K. Onel, L. Tucker, K. M. O'Neil, M. Punaro, D. M. Levy, K. Haines, A. Martini, N. Ruperto, D. Lovell and H. I. Brunner | Annals of the Rheumatic Diseases, 73 401-406 (2), 2014. | 2014 |
| Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry | R. Sobel, D. Lovell, H. Brunner, J. Weiss, P. Morris, B. Gottlieb, E. Chalom, L. Jung, K. Onel, L. Petiniot, D. Goldsmith, K. Nanda, M. Shishov, S. Abramsky, J. Young, E. Giannini and the Pediatric Rheumatology Collaborative Study Group | Pediatric Rheumatology, 12 29 (1), 2014. | 2014 |
| Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis | S. Davi, F. Minoia, A. Pistorio, A. Horne, A. Consolaro, S. Rosina, F. Bovis, R. Cimaz, M. L. Gamir, N. T. Ilowite, I. Kone-Paut, S. K. Feitosa de Oliveira, D. McCurdy, C. A. Silva, F. Sztajnbok, E. Tsitsami, E. Unsal, J. E. Weiss, N. Wulffraat, M. Abinun, A. Aggarwal, M. T. Apaz, I. Astigarraga, F. Corona, R. Cuttica, G. D'Angelo, E. M. Eisenstein, S. Hashad, L. Lepore, V. Mulaosmanovic, S. Nielsen, S. Prahalad, D. Rigante, V. Stanevicha, G. Sterba, G. Susic, S. Takei, R. Trauzeddel, M. Zletni, N. Ruperto, A. Martini, R. Q. Cron, A. Ravelli and on behalf of the Paediatric Rheumatology International Trials Organisation, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society | Arthritis Rheumatology, 66 2871-2880 (10), 2014. | 2014 |
| Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis | C. A. Wallace, E. H. Giannini, S. J. Spalding, P. J. Hashkes, K. M. O'Neil, A. S. Zeft, I. S. Szer, S. Ringold, H. I. Brunner, L. E. Schanberg, R. P. Sundel, D. Milojevic, M. G. Punaro, P. Chira, B. S. Gottlieb, G. C. Higgins, N. T. Ilowite, Y. Kimura, S. Hamilton, A. Johnson, B. Huang, D. J. Lovell, for the Childhood Arthritis and R. R. Alliance | Arthritis Rheumatism, 64 2012-2021 (6), 2012. | 2012 |
| Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis | F. De Benedetti, H. I. Brunner, N. Ruperto, A. Kenwright, S. Wright, I. Calvo, R. Cuttica, A. Ravelli, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, E. Baildam, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Merino, R. Joos, A. Grom, N. Wulffraat, Z. Zuber, F. Zulian, D. Lovell and A. Martini | New England Journal of Medicine, 367 2385-2395 (25), 2012. | 2012 |
| Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis | N. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, N. Wulffraat, G. Horneff, R. Brik, L. McCann, O. Kasapcopur, L. Rutkowska-Sak, R. Schneider, Y. Berkun, I. Calvo, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, S. K. Oliveira, Y. Uziel, S. Viola, K. Nistala, C. Wouters, R. Cimaz, M. A. Ferrandiz, B. Flato, M. L. Gamir, I. Kone-Paut, A. Grom, B. Magnusson, S. Ozen, F. Sztajnbok, K. Lheritier, K. Abrams, D. Kim, A. Martini and D. J. Lovell | New England Journal of Medicine, 367 2396-2406 (25), 2012. | 2012 |
| Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications | A. B. Gottlieb, K. Gordon, E. H. Giannini, P. Mease, J. Li, Y. Chon, J. Maddox, H. H. Weng, J. Wajdula, S. L. Lin and S. W. Baumgartner | J Drugs Dermatol, 10 289-300 (), 2011. | 2011 |
| American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis | C. A. Wallace, E. H. Giannini, B. Huang, L. Itert, N. Ruperto, C. A. R. R. A. (CARRA), P. R. C. S. G. (PRCSG) and P. R. I. T. O. (PRINTO) | Arthritis Care Research, 63 929-936 (7), 2011. | 2011 |
| Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritis | D. J. Lovell, M. H. Passo, T. Beukelman, S. L. Bowyer, B. S. Gottlieb, M. Henrickson, N. T. Ilowite, Y. Kimura, E. M. DeWitt, J. Segerman, L. D. Stein, J. Taylor, R. K. Vehe and E. H. Giannini | Arthritis Care Research, 63 10-16 (1), 2011. | 2011 |
| Juvenile idiopathic arthritis: state of the art and future perspectives | A. Martini and D. Lovell | Ann Rheum Dis, (7) 1260-3 (), 2010. | 2010 |
| Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis | E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. Reiff, G. Higgins, B. Gottlieb, P. R. C. S. Group, Y. Chon, N. Zhang and S. W. Baumgartner | Arthritis Rheumatism, 62 3259-3264 (11), 2010. | 2010 |
| The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis | N. Ruperto, A. Pistorio, A. Ravelli, L. G. Rider, C. Pilkington, S. Oliveira, N. Wulffraat, G. Espada, S. Garay, R. Cuttica, M. Hofer, P. Quartier, J. Melo-Gomes, A. M. Reed, M. Wierzbowska, B. M. Feldman, M. Harjacek, H.-I. Huppertz, S. Nielsen, B. Flato, P. Lahdenne, H. Michels, K. J. Murray, L. Punaro, R. Rennebohm, R. Russo, Z. Balogh, M. Rooney, L. M. Pachman, C. Wallace, P. Hashkes, D. J. Lovell, E. H. Giannini, B. A. Gare and A. Martini | Arthritis Care Research, 62 1533-1541 (11), 2010. | 2010 |
| Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis | N. Ruperto, D. J. Lovell, P. Quartier, E. Paz, N. Rubio-Pérez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. Saad-Magalhães, J. Chavez-Corrales, C. Huemer, A. Kivitz, F. J. Blanco, I. Foeldvari, M. Hofer, G. Horneff, H.-I. Huppertz, C. Job-Deslandre, A. Loy, K. Minden, M. Punaro, A. F. Nunez, L. H. Sigal, A. J. Block, M. Nys, A. Martini and E. H. Giannini | Arthritis Rheumatism, 62 1792-1802 (6), 2010. | 2010 |
| Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis | N. Ruperto, D. J. Lovell, T. Li, F. Sztajnbok, C. Goldenstein-Schainberg, M. Scheinberg, I. C. Penades, M. Fischbach, J. O. Alcala, P. J. Hashkes, C. Hom, L. Jung, L. Lepore, S. Oliveira, C. Wallace, M. Alessio, P. Quartier, E. Cortis, A. Eberhard, G. Simonini, I. Lemelle, E. C. Chalom, L. H. Sigal, A. Block, A. Covucci, M. Nys, A. Martini and E. H. Giannini | Arthritis Care Research, 62 1542-1551 (11), 2010. | 2010 |
| Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension | N. Ruperto, D. Lovell, R. Cuttica, P. Woo, S. Meiorin, e. a. , P. R. I. T. O. (P. and P. R. C. S. G. (PRCSG) | Ann Rheum Dis, 4 712-22 (), 2010. | 2010 |
| Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs | N. Ruperto, E. H. Giannini, A. Pistorio, H. I. Brunner, A. Martini and D. J. Lovell | Arthritis Rheumatism, 62 3131-3139 (11), 2010. | 2010 |
| Summary of worldwide pediatric malignancies reported after exposure to etanercept | P. McCroskery, C. A. Wallace, D. J. Lovell, S. Stryker, N. Chernyukhin, C. Blosch and D. J. Zack | Pediatr Rheumatol Online J, 8 18 (), 2010. | 2010 |
| EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria | S. Ozen, A. Pistorio, S. M. Iusan, A. Bakkaloglu, T. Herlin, R. Brik, A. Buoncompagni, C. Lazar, I. Bilge, Y. Uziel, D. Rigante, L. Cantarini, M. O. Hilario, C. A. Silva, M. Alegria, X. Norambuena, A. Belot, Y. Berkun, A. I. Estrella, A. N. Olivieri, M. G. Alpigiani, I. Rumba, F. Sztajnbok, L. Tambic-Bukovac, L. Breda, S. Al-Mayouf, D. Mihaylova, V. Chasnyk, C. Sengler, M. Klein-Gitelman, D. Djeddi, L. Nuno, C. Pruunsild, J. Brunner, A. Kondi, K. Pagava, S. Pederzoli, A. Martini, N. Ruperto and for the Paediatric Rheumatology International Trials Organisation (PRINTO) | Annals of the Rheumatic Diseases, 69 798-806 (5), 2010. | 2010 |
| The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial | S. Visvanathan, C. Wagner, J. C. Marini, D. J. Lovell, A. Martini, R. Petty, R. Cuttica, P. Woo, G. Espada, M. Gattorno, M. T. Apaz, E. Baildam, A. Fasth, V. Gerloni, P. Lahdenne, P. Quartier, R. Saurenmann, S. Travers, A. Mendelsohn, S. Xu, E. H. Giannini and N. Ruperto | Pediatr Rheumatol Online J, 8 24 (), 2010. | 2010 |
| Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis | E. Giannini, N. Ilowite, D. Lovell, C. Wallace, C. Rabinovich and e. a. | Arthritis Rheum, 60 2794-804 (9), 2009. | 2009 |
| Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases | G. Burmester, P. Mease, B. Dinkmans, K. Gordon and D. Lovell | Ann Rheum Dis, 1863-9 (), 2009. | 2009 |
| A prospecitive study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis | I. Foeldvari, I. Szer, L. Zemel, D. Lovell and E. Giannini | J Rheumatol, 36 (1) 174-82 (), 2009. | 2009 |
| Adalimumab with or without methotrexate in juvenile rheumatoid arthritis | D. Lovell, N. Ruperto, S. Goodman and A. Reiff | N Engl J Med, 359 (8) 810-820 (), 2008. | 2008 |
| A randomized, placebo-controlled trial of adalimumab with or without methotrexate in children with polyarticular juvenile rheumatoid arthritis | D. Lovell, N. Ruperto, S. Goodman, A. Reiff, L. Jung, K. Jarosova, D. Nemcova, R. Mouy, C. Sandborg, J. Bohnsack, D. Elewaut, I. Foeldvari, V. Gerloni, J. Rovensky, K. Minden, R. Vehe, L. Wagner-Weiner, G. Horneff, H. Huppertz, N. Olson, J. Medich, R. Carcereri-De-Prati, M. McIlraith, E. Giannini and A. Martini | N Engl J Med, Vol. 359 810-820 (No. 8), 2008. | 2008 |
| Safety and Efficacy of up to 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis | e. a. Lovell DJ, A. Reiff, N. Ilowite, C. Wallace, Y. Chon, S. Lin, S. Baumgartner and E. Giannini | Arthritis Rheum, 58 1496-504 ((5)), 2008. | 2008 |
| The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study. | N. Ruperto, A. Ravelli, A. Pistorio, V. Ferriani, I. Calvo, G. Ganser, J. Brunner, G. Dannecker, C. Silva, V. Stanevicha, R. Cate, L. van Suijlekom-Smit, O. Voygioyka, M. Fischbach, I. Foeldvari, O. Hilario, C. Modesto, R. Saurenmann, M. Sauvain, I. Scheibel, D. Sommelet, L. Tambic-Bukovac, R. Barcellona, R. Brik, S. Ehl, M. Jovanovic, J. Rovensky, F. Bagnasco, D. Lovell and A. Martini | Arthritis Rheum, 59 (1) 4-13 (), 2008. | 2008 |
| Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial | N. Ruperto, D. Lovell and E. Giannini | Lancet, 372 (9636) 383-391 (), 2008. | 2008 |
| Efficacy and safety of abatacept in children with juvenile idiopathic arthritis: A randomized, double-blink, placebo controlled withdrawal trial | N. Ruperto, D. Lovell, E. Giannini and A. Martini | Lancet, 372 383-391 (), 2008. | 2008 |
| A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis | N. Ruperto, D. Lovell, R. Cuttica, N. Wilkinson, P. Woo, G. Espada, C. Wouters, E. Silverman, Z. Balogh, M. Henrickson, M. Apaz, E. Baildam, A. Fasth, V. Gerloni, P. Lahdenne, A. Prieur, A. Ravelli, R. Saurenmann, M. Gamir, N. Wulffraat, L. Marodi, R. Petty, R. Joos, F. Zulian, D. McCurdy, B. Myones, K. Nagy, P. Reuman, I. Szer, S. Travers, A. Beutler, G. Keenan, J. Clark, S. Visvanathan, A. Fasanmade, A. Raychaudhuri, A. Mendelsohn, A. Martini and E. Giannini | Arthritis Rheum, 56 3096-3106 (), 2007. | 2007 |
| Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. | A. Reiff, D. Lovell, J. Van Adelsberg, M. Kiss, S. Goodman, M. Zavaler, P. Chen, J. Bolognese, P. Cavanaugh Jr, A. Reicin and E. Giannini | J Rheumatol, 33 985-995 (5), 2006. | 2006 |
| Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis | D. Lovell, A. Reiff and O. Jones | Arthritis Rheumatism, 54 1987-1994 (), 2006. | 2006 |
| Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. | N. Ruperto, A. Ravelli, E. Castell, V. Gerloni, R. Haefner, C. Malattia, F. Kanakoudi-Tsakalidou, S. Nielsen, J. Bohnsack, D. Gibbas, R. Rennebohm, O. Voygioyka, Z. Balogh, L. Lepore, E. Macejkova, N. Wulffraat, S. Oliveira, R. Russo, A. Buoncompagni, M. O. Hilario, M. G. Alpigiani, M. Passo, D. J. Lovell, R. Merino, A. Martini and E. H. Giannini | Clin Exp Rheumatol, 24 599-605 (5), 2006. | 2006 |
| Preliminary criteria for clinical remission for selected categories of juvenile idiopathic arthritis | C. Wallace, N. Ruperto and E. Giannini | J Rheumatol, 31 2290-2294 (), 2004. | 2004 |
| International consensus on preliminary definitions of improvement in adult and juvenile myositis. | L. Rider, E. Giannini, H. Brunner, N. Ruperto, L. James-Newton, A. Reed, P. Lachenbruch and F. Miller | Arthritis Rheum, 50 2281-90 (7), 2004. | 2004 |
| Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. | D. Lovell, E. Giannini, A. Reiff, O. Jones, R. Schneider, J. Olson, L. Stein, A. Gedalia, N. Ilowite, C. Wallace, M. Lange, B. Finck and D. Burge | Arthritis Rheum, 48 218-26 (1), 2003. | 2003 |
| Defining Clinical Improvement in Adult and Juvenile Myositis | L. Rider, E. Giannini, M. Harris-Love, G. Joe, D. Isenberg, C. Pilkington, P. Lachenbruch and F. Miller | J Rheumatol, 30 603-617 ((3)), 2003. | 2003 |
| Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. | N. Ruperto, A. Ravelli, K. Murray, D. Lovell, B. Andersson-Gare, B. Feldman, S. Garay, W. Kuis, C. Machado, L. Pachman, A. Prieur, L. Rider, E. Silverman, E. Tsitsami, P. Woo, E. Giannini and A. Martini | Rheumatology (Oxford), 42 1452-9 (12), 2003. | 2003 |
| Preliminary definitions of disease flare in juvenile rheumatoid arthritis (JRA). | H. Brunner, D. Lovell, B. Finck and E. Giannini | J Rheumatol, 29 1058-64 (), 2002. | 2002 |
| Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. | D. Lovell, E. Giannini, A. Reiff, G. Cawkwell, E. Silverman, J. Nocton, L. Stein, A. Gedalia, N. Ilowite, C. Wallace, J. Whitmore and B. Finck | N Engl J Med, 342 763-9 (11), 2000. | 2000 |
| Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. | D. J. Lovell, C. B. Lindsley, R. M. Rennebohm, S. H. Ballinger, S. L. Bowyer, E. H. Giannini, J. E. Hicks, J. E. Levinson, R. Mier, L. M. Pachman, M. H. Passo, M. D. Perez, A. M. Reed, K. N. Schikler, M. Smith, L. S. Zemel and L. G. Rider | Arthritis Rheum, 42 2213-9 (10), 1999. | 1999 |
| Preliminary definition of improvement in juvenile arthritis. | E. H. Giannini, N. Ruperto, A. Ravelli, D. J. Lovell, D. T. Felson and A. Martini | Arthritis Rheum, 40 1202-9 (7), 1997. | 1997 |
| Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status | N. Ruperto, J. Levinson, A. Ravelli, E. Shear, B. Tague, K. Murray, A. Martini and E. Giannini | J Rheumatol, 24 945-951 (), 1997. | 1997 |
| Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. | E. H. Giannini, D. J. Lovell, E. D. Silverman, R. P. Sundel, B. L. Tague and N. Ruperto | J Rheumatol, 23 919-24 (5), 1996. | 1996 |
| Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. | N. Ruperto and E. H. Giannini | Ann Rheum Dis, 55 73-5 (1), 1996. | 1996 |
| FDA draft guidelines for the clinical evaluation of anti-inflammatory and anti-rheumatic drugs in children. Executive summary. | E. H. Giannini, D. J. Lovell and B. Hepburn | Arthritis Rheum, 38 715-8 (5), 1995. | 1995 |
| Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. | E. D. Silverman, G. D. Cawkwell, D. J. Lovell, R. M. Laxer, T. J. Lehman, M. H. Passo, L. S. Zemel and E. H. Giannini | J Rheumatol, 21 2353-8 (12), 1994. | 1994 |
| Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. | E. H. Giannini, J. T. Cassidy, E. J. Brewer, A. Shaikov, A. Maximov and N. Kuzmina | Semin Arthritis Rheum, 23 34-46 (1), 1993. | 1993 |
| Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. | E. H. Giannini, E. J. Brewer, N. Kuzmina, A. Shaikov, A. Maximov, I. Vorontsov, C. W. Fink, A. J. Newman, J. T. Cassidy and L. S. Zemel | N Engl J Med, 326 1043-9 (16), 1992. | 1992 |
| Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial. | E. H. Giannini, K. S. Barron, C. H. Spencer, D. A. Person, J. Baum, B. H. Bernstein, D. W. Kredich, J. C. Jacobs, L. S. Zemel and D. Gibbas | J Rheumatol, 18 1240-2 (8), 1991. | 1991 |
| Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. | E. Giannini, E. Brewer, M. Miller, D. Gibbas, M. Passo, H. Hoyeraal, B. Bernstein, D. Person, C. Fink and L. Sawyer | J Pediatr, 117 645-52 (4), 1990. | 1990 |
| Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. | E. H. Giannini, E. J. J. Brewer, N. Kuzmina, A. Shaikov and B. Wallin | Arthritis Rheum, 33 466-76 (4), 1990. | 1990 |
| Temporal patterns of response to D-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients. | C. van Kerckhove, E. H. Giannini and D. J. Lovell | Arthritis Rheum, 31 1252-8 (10), 1988. | 1988 |
| Characteristics of responders and nonresponders to slow-acting anti-rheumatic drugs (SAARDs) in juvenile rheumatoid arthritis. | E. H. Giannini, E. J. Brewer, N. Kuzmina, L. Alekseev and B. P. Shokh | Arthritis Rheum, 31 15-20 (1), 1988. | 1988 |
| Arthritis/arthralgia and hypermobility of the joints in schoolchildren. | I. L. Arroyo, E. J. Brewer and E. H. Giannini | J Rheumatol, 15 978-80 (6), 1988. | 1988 |
| HLA-B27-associated arthropathy in childhood: Long-term clinical and diagnostic outcome. | K. A. Sheerin, E. H. Giannini, E. J. J. Brewer and K. S. Barron | Arthritis Rheum, 31 1165-70 (9), 1988. | 1988 |
| Poor correlation between the erythrocyte sedimentation rate and clinical activity in juvenile rheumatoid arthritis. | E. H. Giannini and E. J. Brewer | Clin Rheumatol, 6 197-201 (2), 1987. | 1987 |
| Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. | E. Brewer, E. Giannini, N. Kuzmina and L. Alekseev | N Engl J Med, 314 1269-76 (20), 1986. | 1986 |
| Long-term auranofin therapy in patients with juvenile rheumatoid arthritis | E. Giannini, E. Brewer, D. Person and X. He | J Rheumatol, 314 1269-1276 (), 1986. | 1986 |
| Hypermobility of the joints in juvenile episodic arthritis/arthralgia. | A. Gedalia, D. A. Person, E. J. J. Brewer and E. H. Giannini | J Pediatr, 107 873-6 (6), 1985. | 1985 |
| A once-daily anti-inflammatory drug, oxaprozin, in the treatment of juvenile rheumatoid arthritis. The Pediatric Rheumatology Collaborative Study Group. | J. C. Bass, B. H. Athreya, E. J. Brewer, E. H. Giannini, D. P. Goldsmith, J. R. Hollister, D. W. Kredich, N. E. Brandstrup, J. J. Miller and L. M. Pachman | J Rheumatol, 12 384-6 (2), 1985. | 1985 |
| Time course of response to non-steroidal anti-inflammatory drugs in juvenile rheumatoid arthritis. | D. J. Lovell, E. H. Giannini and E. J. J. Brewer | Arthritis Rheum, 27 1433-7 (12), 1984. | 1984 |
| Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy. | E. H. Giannini, E. J. Brewer and D. A. Person | Ann Rheum Dis, 43 228-31 (2), 1984. | 1984 |
| Blood and serum concentrations of gold after a single dose of auranofin in children with juvenile rheumatoid arthritis. | E. H. Giannini, D. A. Person, E. J. Brewer and D. B. Parks | J Rheumatol, 10 496-8 (3), 1983. | 1983 |
| Auranofin in the treatment of juvenile rheumatoid arthritis. | E. H. Giannini, E. J. J. Brewer and D. A. Person | AJ Pediatr, 102 138-41 (1), 1983. | 1983 |
| Early experiences with auranofin in juvenile rheumatoid arthritis. | E. J. J. Brewer, E. H. Giannini and D. A. Person | Am J Med, 75 152-6 (6A), 1983. | 1983 |
| Proquazone (Biarsan) in the treatment of juvenile rheumatoid arthritis. A segment I study. | E. Brewer, E. Giannini, J. Baum, C. Fink, V. Hanson, J. Jacobs and J. Schaller | J Rheumatol, 9 135-139 (), 1982. | 1982 |
| Sodium meclofenamate (Meclomen) in the treatment of juvenile rheumatoid arthritis. A segment I study. | E. Brewer, E. Giannini, J. Baum, J. Cassidy, C. Fink, V. Hanson, J. Jacobs and J. Schaller | J Rheumatol, 9 129-134 (), 1982. | 1982 |
| Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data | E. H. Giannini and E. J. Brewer | J Rheumatol, 9 114-122 (1), 1982. | 1982 |
| Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. | E. J. Brewer and E. H. Giannini | J Rheumatol, 9 109-13 (1), 1982. | 1982 |
| Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial. A segment II study | E. J. Brewer, E. H. Giannini, J. Baum, B. Bernstein, C. W. Fink, H. M. Emery and J. G. Schaller | J Rheumatol, 9 123-128 (1), 1982. | 1982 |
| Ketoprofen (Orudis) in the treatment of juvenile rheumatoid arthritis. A segment I study | E. J. Brewer, E. H. Giannini, J. Baum, B. Bernstein, C. W. Fink, J. G. Schaller and C. M. Knee | J Rheumatol, 9 144-148 (1), 1982. | 1982 |
| Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis. A segment I study. | J. Bass, E. Giannini, E. Brewer, B. Athreya, N. Brandstrup, D. Goldsmith, J. Miller and L. Pachman | J Rheumatol, 9 140-3 (1), 1982. | 1982 |
| Plasma exchange in selected patients with juvenile rheumatoid arthritis. | E. Brewer, R. Nickeson, R. Rossen, D. Person, E. Giannini and J. Milam | J Pediatr, 98 194-200 (), 1981. | 1981 |
| Gold Therapy in the Management of Juvenile Rheumatoid Arthritis | E. Brewer, E. Giannini and E. Barkley | Arthritis Rheum, 23 404-411 (), 1980. | 1980 |
| Plasma exchange therapy of a childhood onset dermatomyositis patient. | E. Brewer, E. Giannini, R. Rossen, B. Patten and E. Barkley | Arthritis Rheum, 23 509-513 (), 1980. | 1980 |
| Comparison of tometin sodium and aspirin in the treatment of juvenile rheumatoid arthritis | J. Levinson, J. Baum, E. Brewer Jr, C. Fink, V. Hanson and J. Schaller | J Pediatr, 91 799-804 (5), 1977. | 1977 |
| New medicines for childhood-onset systemic lupus erythematosus: an EU perspective on paediatric drug development | Roberto De Lisa, Fernando de Andres Trelles, Ralph Bax, Sara Galluzzo, Brian Alward, Andrew Thomson1, Dominik Karres, Hermine I Brunner, Nicolino Ruperto, Gunter F Egger. | Frontiers in Medicine 12: 1583140.; PMID: 40708640 | 2025 |
| Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients with Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-label, Phase 1 Trial | Hermine I Brunner MD, Anna Shmagel MD, Gerd Horneff MD, Ivan Foeldvari MD, Jordi Antón MD, Athimalaipet V. Ramanan MD, Yuli Qian PhD, Kristina Unnebrink PhD, Shuai Hao PhD, Heidi S. Camp PhD, Nasser Khan MD, Wei Liu PhD, Mohamed-Eslam F Mohamed PhD | Arthritis Care & Research. https://doi.org/10.1002/acr.25465 | 2024 |
| 25 Years of Biologics For The Treatment of Pediatric Rheumatic Diseases – Advances in Prognosis and Ongoing Challenges | Shishov M, Weiss PF, Levy DM, Chang JC, Angeles-Han ST, Ogbu EA, Nanda K, Sherrard TM, Goldmuntz E, Lovell DJ, Rider LG, Brunner HI; of the PRCSG Advisory Council. | Arthritis Care Res (Hoboken). 2024 Dec 9. https://doi.org/10.1002/acr.25482 Epub ahead of print. PMID: 39651592. | 2024 |
| Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis | Ekemini A Ogbu, Hermine I Brunner, Esraa Eloseily, Brubul Aviel, Kabita Nanda, Heinricke Schmeling, Heather Tory, Joseph Uziel, Diego Oskar Viola, Dawn Wahezi, Stacey Tarvin, Alyssa Sproles, Chen Chen, Nicola Ruperto, Bin Huang, Alexei Grom, Sherry Thornton | Arthritis Care Res (Hoboken). 2024 Dec;76(12):1723-1732. doi: 10.1002/acr.25417. Epub 2024 Sep 17 | 2024 |